Vol 8, No 1 (2017)
Case report
Published online: 2017-06-02

open access

Page views 1113
Article views/downloads 3404
Get Citation

Connect on Social Media

Connect on Social Media

Planned pregnancy pregnancy in patient with chronic myelogenous leukemia treated with imatinib

Ilona Seferyńska1, Iwona Solarska2, Krzysztof Warzocha1
Hematologia 2017;8(1):79-84.

Abstract

Tyrosine kinase inhibitors (TKI) used in the treatment of chronic myelogenous leukemia (CML) can cause disturbances in fetal development in pregnant women. Women of childbearing potential are recommended to practice effective contraception. Women who want to become pregnant should stopped treatment with TKI before and during pregnancy. The optimal time to stop treatment is deep molecular response after minimum 2 years of treatment. We present a case study of a 24-year- -old female patient with CML, diagnosed in myeloblastic phase. After treatment with imatinib deep and permanent molecular remission was achieved. Treatment was interrupted after 5 years in order to become pregnant. During pregnancy increase in BCR-ABL1 transcript was observed and treatment with interferon a was introduced. The baby was healthy. The imatinib was reintroduced, after 3 months deep molecular response was achieved.

References

  1. Apperley J. Chronic myeloid leukaemia. The Lancet. 2015; 385(9976): 1447–1459.
  2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872–884.
  3. Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015; 15(6): 323–334.
  4. Palani R, Milojkovic D, Apperley JF, et al. How I treat leukemia during pregnancy. Blood. 2014; 123(7): 974–984, doi: 10. 1182/ /blood-2013-08-283580, indexed in Pubmed. ; 24269956.
  5. Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol. 2015; 94 Suppl 2: S167–S176.
  6. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development. 1997; 124(14): 2691–2700.
  7. Arnall J, Muluneh B. Loss of pregnancy in a patient with chronic myeloid leukemia during treatment with nilotinib. J Hematol Oncol Pharm. 2016; 6(1): 22–27.
  8. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006; 24(7): 1204–1208.
  9. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008; 111(12): 5505–5508.
  10. Abruzzese E, Trawinska MM, Perrotti AP, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014; 6(1): e2014028.
  11. Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res. 2008; 32(3): 519–520.
  12. Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol. 2007; 137(4): 374–375.
  13. Zhou Li, You JH, Wu W, et al. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013; 37(10): 1216–1221.
  14. Rea D, Nicolini FE, Tulliez M, et al. France Intergroupe des Leucémies Myéloïdes Chroniques. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017; 129(7): 846–854.
  15. Mahon FX. Discontinuation of tyrosine kinase therapy in CML. Ann Hematol. 2015; 94 Suppl 2: S187–S193.
  16. Mahon FX, Réa D, Guilhot J, et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029–1035.
  17. Ali R, Ozkalemkaş F, Ozkocaman V, et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol. 2004; 34(4): 215–217.
  18. Mahon FX, Richter J, Guilhot J, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood. 2016; 128(22): 787.
  19. Etienne G, Guilhot J, Rea D, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017; 35(3): 298–305.
  20. Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001; 15(8): 1309–1311.
  21. Hiratsuka M, Minakami H, Koshizuka S, et al. Administration of interferon-alpha during pregnancy: effects on fetus. J Perinat Med. 2000; 28(5): 372–376.
  22. Mubarak AAS, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002; 69(2): 115–118.
  23. Regierer AC, Schulz CO, Kuehnhardt D, et al. Interferon-alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol. 2006; 81(2): 149–150.
  24. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003; 40(2 Suppl 2): 21–25.
  25. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007; 27(4): 241–243.



Hematology in Clinical Practice